• lloydczaplewski

How will history judge our current response to antimicrobial resistance?

I’m interested in considering how a scientist or historian might judge current responses to antimicrobial resistance in 30, 100 or 300 years and whether looking through that lens offers any insights into what we could do differently now!


Now is a truly remarkable time to be engaged in antimicrobial resistance. The decades long perceived threat is now a reality with an estimated >1m deaths per year (The Lancet). The urgency is obvious. The last two-decades has seen a remarkable transition from a major Pharma led-antibiotic industry to a biotech/academic led-response. In parallel, awesome organisations have developed to nurture the field including CARB-X, BARDA, GARDP, Novo Repair Impact Fund, AMR Action Fund, WHO and others. Alternative financial models e.g. subscription models, to encourage antibacterial R&D are an emerging reality. There is more enthusiasm and momentum in this space than there has been for the last 20-years. World-wide interest in infectious diseases, driven by the pandemic, may make microbiology and antibiotic R&D sexy again.


I do worry that, in the short term, in the search for new antibacterials to treat patients, we are overly attracted to innovation rather than pragmatism.


I have two key questions for you:

What if there were no good new antibiotic chemical classes?

What if there were no good new antibiotic targets?


A scientist or historian reviewing our current activities, with the benefit of 30, 100 or 300 years hindsight, would almost certainly conclude that it would have made sense to completely exhaust any opportunities in the known antibiotic chemical classes and clinically validated antibiotic targets as soon as possible. It does not make any sense to wait for decades before doing so.


But the antimicrobial resistance community, scientists, and funders, largely ignore the known, in search of innovation and novelty.


Acquiring funding to explore traditional antibiotic chemical classes such as the beta-lactams, macrolides, aminoglycosides, tetracyclines or their targets can be exceptionally challenging, perhaps because of a perception that they have been mined to death.


In this blog I am going to explore some of these options and will encourage the community to engage with this discussion so that we might perhaps identify some areas that merit investigation.

75 views1 comment

Recent Posts

See All

Discovering, developing and commercialising novel antibacterials is hard. The science is tough, finding funding is challenging and if successful, the commercial rewards are insignificant. We have seen

The recent publication of the output from the Global Research on AntiMicrobial resistance (GRAM) project in the Lancet provides the most comprehensive estimate of the AMR burden to date. The headline